Meeting Materials
Coming soon
Coming soon
Dr. Tanios Bekaii-Saab is a Medical Oncologist at Mayo Clinic. Dr. Bekaii-Saab’s research interests include experimental therapeutics/translational research focused on GI malignancies, molecular-targeted and immune therapies.
In this masterclass, Drs. Bekaii-Saab and Ahn will discuss data from the ReDOS trial. Best practice approaches to later-line management of mCRC through individualizing treatment, managing side effects and involving the wider multi-disciplinary team.
Dr. Efrat Dotan is an Assistant Professor of Medical Oncology at Fox Chase Cancer Center, in Philadelphia. Dr. Dotan specializes in the management of patients with GI malignancies. Her research interests include the development of new treatment options for patients with GI cancers and the management of older patients with cancer.
Dr. Dotan will provide her perspective on collaborative strategies between patient and doctor to improve treatment outcomes via shared decision-making. The discussion will move on to take into consideration how to address interactions with elderly patients. CRC patients will also be present to share their insights and perspectives on shared decision-making.
Dr. Joleen Hubbard is an Assistant Professor of Medical Oncology at Mayo Clinic. Dr. Hubbard specializes in the treatment of GI cancers, focusing on CRC. Her research interests include the evaluation of novel therapies for GI cancers and geriatric oncology with a special interest in clinical and biologic markers of frailty.
During the educational program Dr. Hubbard will be asking you to join her in considering and evaluating options for patients with relapsing mCRC whose disease has progressed on first or second-line therapy. The debate will cover currently available and emerging therapies, optimal sequencing of agents, and goals of therapy in the later-line setting.
Dr. Autumn McRee is an Associate Professor of Medicine specializing in GI medical oncology at The University of North Carolina. Her clinical interests include the multi-disciplinary management of patients with GI malignancies, with a focus on clinical trials designed to investigate new promising treatments for these patients.
In this masterclass, Dr. McRee will discuss new biological insights and recent therapeutic advances in in the treatment and management of mCRC.
Dr. Shubham Pant is a Hematologist-Oncologist and an Associate Professor of Medicine at University of Texas MD Anderson Cancer Center in Houston. Dr. Pant’s clinical interests include early drug development, targeted therapy and immunotherapy. In addition, Dr. Pant has an interest in improving quality of care for patients with cancer.
Dr. Pant will be using the opportunity of an interactive masterclass to help bring to life the SHARE Communication Framework for shared decision-making with patients, and in particular those with progressive mCRC. The session will focus not only on the science and the ‘what’ has to be communicated, but also the ‘how’ the key messages are best delivered.
Dr. Fotios Loupakis is a Medical Oncologist at the Instituto Oncologico Veneto in Padova, Italy. His research interests include translational preclinical and clinical studies on novel therapeutic approaches in CRC.
In an interactive session, Dr. Loupakis will guide the group discussion about the challenges in treating mCRC. Dr. Loupakis was involved in the original TRIBE study and is therefore well placed to input into the discussion on which upfront therapy should be used first in the treatment of mCRC. The debate will cover a wide range of issues in the management of mCRC through the use of interactive case presentations.
Dr. Daniel Ahn is Dr. of osteopathic medicine at Mayo Clinic and specializes in the management of patients with GI malignancies. His clinical and research interests include phase 1 drug development, gastrointestinal neuroendocrine cancer, pancreatic cancer, bile duct cancer, gastric cancer, esophageal cancer, and CRC.
In this masterclass, Drs. Bekaii-Saab and Ahn will discuss data from the ReDOS trial. Best practice approaches to later-line management of mCRC through individualizing treatment, managing side effects and involving the wider multi-disciplinary team.
Dr. Samuel Klempner is a GI medical oncologist with a research and clinical focus on esophagogastric cancers and cancer genomics. Dr. Klempner’s research interests include the intersection of genomics and immunotherapies, oncogene-driven tumors, acquired resistance, and experimental therapeutics.
Dr. Klempner will provide the forward looking view during the program to ignite discussion around immunotherapy, next generation targets and factors influencing treatment decisions and outcomes such as the CMS classification and ACS lifestyle guidelines.
Dr. LeBoeuf received her medical certification from the University of Massachusetts Medical School in 2006. She completed her residency in Dermatology at Columbia University followed by a fellowship in Cutaneous Oncology at Brigham and Women’s/Dana‐Farber Cancer Center at Harvard. Dr. LeBoeuf joined the faculty in the Department of Dermatology and Center for Cutaneous Oncology at Dana‐Farber and Brigham and Women’s in 2012 and earned a Masters in Public Health from the Harvard TH Chan School of Public Health in 2015. In addition to directing the Cutaneous Oncology and Medical Dermatology Fellowship programs, Dr. LeBoeuf established and directs the Program in Skin Toxicities from Anticancer Therapies at the Dana‐Farber/Brigham and Women’s Cancer Center. She leads clinical trials in cutaneous lymphoma and rare skin malignancies as well as interventional studies for the prevention or management of side effects from cancer treatment. Her research focuses on understanding the immunologic mechanisms of side effects to cancer therapeutics and implementing therapies or other interventions to mitigate them.